Geron stock trades at USD 1.30 as market cap reaches USD 835.2 million

Published on 09/22/2026 at 12:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Geron stock traded at USD 1.30 on September 22, 2026, with a market capitalization of USD 835.2 million. The latest reported period supplies the earnings frame.

GERN, US3741631036, Illustration mit AI erstellt.

Geron Corporation (ISIN US3741631036) traded at USD 1.30 on the Nasdaq on September 22, 2026, down 1.52 percent from the prior close. The quoted market capitalization was USD 835.215 million, giving the session a concrete valuation frame.

Price data define the session

The latest available quote also shows average volume of 2,982,292 shares and a market beta of 2.24 in the September 22, 2026 market snapshot. At USD 1.30, the stock remains a small-cap biotechnology security whose daily percentage move can materially change its market value.

The same snapshot lists analyst price targets ranging from USD 55.00 to USD 91.00, with an average of USD 71.65. Those figures describe published estimates rather than a forecast by this article, and the gap between the USD 1.30 quote and the USD 71.65 average illustrates the high-risk nature of valuation assumptions for a development-stage drug company.

Reported figures remain the anchor

The September 22, 2026 market data identify Geron as the issuer behind the GERN ticker and provide the latest earnings comparison shown in the quote overview. The cited snapshot labels the second quarter of fiscal 2026 with revenue of USD 0 and earnings of negative USD 158.99 million, while the earnings comparison shows a quarter estimate of negative USD 0.55 against an actual negative USD 1.44.

That difference of USD 0.89 per share between the estimate and the reported actual is the clearest quantified operating comparison in the available data. It also explains why the stock requires a different reading from a mature profitable company: revenue generation and cash use remain more important than conventional price-to-earnings metrics.

Geron stock remains speculative

The combination of a USD 835.215 million market capitalization, negative USD 158.99 million quarterly earnings and a USD 71.65 average target places clinical and commercial execution at the center of the investment case. The figures are not a buy or sell signal, but they show why percentage moves and target revisions can dominate the daily narrative.

GERN closes at USD 1.30

Geron stock stood at USD 1.30 on the Nasdaq on September 22, 2026, down 1.52 percent from the prior close. Market capitalization was USD 835.215 million on the same dated snapshot.